title: Hyperglycemia and hepatic tumors in ICR mice neonatally injected with streptozotocin.
abstract: Repeated, low-dose administration of streptozotocin (STZ) is widely used to induce insulin-dependent diabetes mellitus in mice. The authors adapted this method using neonatal mice and determined the long-term effects of STZ injection in the mice. After receiving intraperitoneal injections of STZ at postnatal day 3 (P3), P4 and P8, male and female mice were hyperglycemic by week 4. A clear sex difference was found, with blood glucose levels in STZ-treated males remaining higher than those in STZ-treated females until week 23. Whereas STZ-treated males remained hyperglycemic until week 23, STZ-treated females did not have significantly higher glucose levels than control mice after week 18. Additionally, STZ-treated mice had neoplastic lesions in their livers by week 4, with a progression in the severity of these lesions until week 24. The results confirm that, in addition to pancreatic beta cell toxicity, STZ has an oncogenic effect on the liver when administered to neonates.
authors.affiliation: Centre de Biotecnologia Animal i Teràpia Gènica (CBATEG), Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Lorena
authors.initials: L
authors.lastname: Ariza
authors.affiliation: Centre de Biotecnologia Animal i Teràpia Gènica (CBATEG), Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Mireia
authors.initials: M
authors.lastname: Zaguirre
authors.affiliation: 1] Centre de Biotecnologia Animal i Teràpia Gènica (CBATEG), Universitat Autònoma de Barcelona, Barcelona, Spain. [2] Harlan Laboratories, Barcelona, Spain.
authors.forename: Marta
authors.initials: M
authors.lastname: García
authors.affiliation: 1] Centre de Biotecnologia Animal i Teràpia Gènica (CBATEG), Universitat Autònoma de Barcelona, Barcelona, Spain. [2] Departament de Medicina i Cirurgia Animals, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Ester
authors.initials: E
authors.lastname: Blasco
authors.affiliation: 1] Centre de Biotecnologia Animal i Teràpia Gènica (CBATEG), Universitat Autònoma de Barcelona, Barcelona, Spain. [2] Departament de Medicina i Cirurgia Animals, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Rosa Maria
authors.initials: RM
authors.lastname: Rabanal
authors.affiliation: Centre de Biotecnologia Animal i Teràpia Gènica (CBATEG), Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Assumpició
authors.initials: A
authors.lastname: Bosch
authors.affiliation: Centre de Biotecnologia Animal i Teràpia Gènica (CBATEG), Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Pedro José
authors.initials: PJ
authors.lastname: Otaegui
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D001786:Blood Glucose / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D006652:Histological Techniques; D006943:Hyperglycemia / Q000139:chemically induced*; D007274:Injections, Intraperitoneal; D008113:Liver Neoplasms / Q000139:chemically induced*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D012727:Sex Characteristics; D013311:Streptozocin / Q000008:administration & dosage / Q000633:toxicity*
chemical_list: D001786:Blood Glucose; D013311:Streptozocin